Antitrust Antitrust

Comment: Teva’s EU troubles broaden amid claims of blocking generic access

By Lewis Crofts and Max Fillion
  • 12 Nov 2020 11:44
  • 13 Nov 2020 10:02
Teva is facing an EU dominance probe into a treatment for multiple sclerosis, against a backdrop of evidence in the US that the company has been using “exclusionary tactics” through pharmacies and prescriptions to keep cheaper versions off the market.

A recent report by US lawmakers accused Teva of illegal conduct

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News